Sellas Life Sciences Group Report issue

For profit Phase 2 Phase 3
Founded: Hamilton Bermuda (2006)
Status: Acquired by Galena Biopharma, Inc. (2017) → now Sellas (2017)

Organization Overview

First Clinical Trial
2019
NCT03761914
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sellas Life Sciences Group | SELLAS Life Sciences Group, Inc. | Selles Life Sciences Group

Active Ingredients

Drugs in Phase 3 Trials (1)

galinpepimut-s (3 trials)

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2